Neff Thomas B 4

Accession 0001209191-19-045973

CIK 0000921299other

View on SEC.gov Company Profile

Filed

Aug 13, 8:00 PM ET

Accepted

Aug 14, 5:38 PM ET

Size

27.8 KB

Accession

0001209191-19-045973

Insider Transaction Report

Form 4

Period: 2019-08-12

FIBROGEN INCFGEN

Neff Thomas B

DirectorChief Executive Officer10% Owner

Transactions

Exercise/Conversion
Common Stock
2019-08-13$2.90/sh+6,834$19,819→ 2,368,144 total
Sale
Common Stock
2019-08-12$45.04/sh−1,118$50,355→ 48,792 total(indirect: By Partnership)
Sale
Common Stock
2019-08-13$46.19/sh−6,900$318,711→ 2,349,744 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-08-12−6,834→ 198,204 total
Exercise: $2.90Exp: 2020-06-09→ Common Stock (6,834 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-08-13−6,834→ 191,370 total
Exercise: $2.90Exp: 2020-06-09→ Common Stock (6,834 underlying)
Exercise/Conversion
Common Stock
2019-08-12$2.90/sh+6,834$19,819→ 2,379,710 total
Sale
Common Stock
2019-08-12$44.98/sh−10,700$481,286→ 2,369,010 total
Sale
Common Stock
2019-08-12$45.59/sh−7,700$351,043→ 2,361,310 total
Sale
Common Stock
2019-08-12$45.67/sh−300$13,701→ 48,492 total(indirect: By Partnership)
Sale
Common Stock
2019-08-13$46.17/sh−500$23,085→ 47,074 total(indirect: By Partnership)
Sale
Common Stock
2019-08-13$45.33/sh−11,500$521,295→ 2,356,644 total
Sale
Common Stock
2019-08-13$45.31/sh−918$41,595→ 47,574 total(indirect: By Partnership)

Holdings

Common Stock
(indirect: By Spouse)
20,000
Common Stock
(indirect: See footnote)
60,946

Footnotes (11)

[F1]Shares sold pursuant to a 10b5-1 plan.
[F10]The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
[F11]Fully vested.
[F2]The shares were sold at prices ranging from $44.42 to $45.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]The shares were sold at prices ranging from $45.42 to $45.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F4]The shares were sold at prices ranging from $44.50 to $45.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]The shares were sold at prices ranging from $45.515 to $45.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F6]The shares were sold at prices ranging from $44.94 to $45.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F7]The shares were sold at prices ranging from $45.94 to $46.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F8]The shares were sold at prices ranging from $44.98 to $45.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F9]The shares were sold at prices ranging from $46.00 to $46.37. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

FIBROGEN INC

CIK 0000921299

→

Entity typeother

Related Parties

filerCIK 0001623238

Filing Metadata

Form type: 4
Filed: Aug 13, 8:00 PM ET
Accepted: Aug 14, 5:38 PM ET
Size: 27.8 KB

View on SEC.gov